Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 426 - 450 of 673 Clear search
Zyme Communications
Healthcare and Life Science 18 Jul 2023

Arrayjet announces collaboration with Chemspace to augment its small molecule microarray services for drug discovery

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that it has partnered with Chemspace, the largest online catalogue of small molecules and biologics, to augment and streamline the Company’s small molecule microarray (SMM) service offering. Chemspace’s curated and deeply annotated compound libraries are now accessible through Arrayjet’s SMM CRO/CMO services for…

Zyme Communications
Healthcare and Life Science 11 Jul 2023

Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy

Grant award of £1.6M supports program of development work with Cell and Gene Therapy Catapult NK:IO’s platform, based on pioneering discoveries in NK cell biology, yields industry-leading tumour killing and cell production

Zyme Communications
Healthcare and Life Science 06 Jul 2023

Metrion Biosciences expands senior leadership team with appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO

Dr Stevens promoted from Director of Drug Discovery, and Dr Kirby promoted from Director of Operations

Zyme Communications
Healthcare and Life Science 22 Jun 2023

FUJIFILM Irvine Scientific offers expanded capabilities of Presagen’s Life Whisperer Platform to aid with Clinical Decision-making in IVF

SANTA ANA, California - FUJIFILM Irvine Scientific, Inc., a global leader in the innovation and manufacture of cell culture solutions for the Life Science and Medical markets, announces the addition of the Life Whisperer Genetics module to its Life Whisperer software package (launched in 2021)1, enabling non-invasive evaluation of embryo genetic integrity during in vitro fertilization (IVF).

Zyme Communications
Healthcare and Life Science 21 Jun 2023

Avacta announces successful completion of fifth dose escalation in AVA6000 Phase 1 clinical study

Very positive safety profile of AVA6000 continues to be observed in the fifth cohort Several patients remain on trial in different dose cohorts and continue to receive AVA6000 as their disease has not progressed

London and Wetherby, UK, 21

Zyme Communications
Healthcare and Life Science 20 Jun 2023

Closed Loop Medicine appoints Kate Woolland as Chief Operating Officer

Key executive appointment supports strategic operational delivery of the Company’s product and partnership programs

Zyme Communications
Healthcare and Life Science 20 Jun 2023

H.E.L Group expands into new purpose-designed facilities

·        Investment in new global headquarters forms part of ongoing growth plans

Zyme Communications
Healthcare and Life Science 19 Jun 2023

Avacta appoints Shaun Chilton as Non-executive Director

Appointment brings additional, significant commercial and corporate development experience to the Board

Zyme Communications
Healthcare and Life Science 12 Jun 2023

Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations

Appointment supports growth of Metrion’s pre-clinical ion channel contract research and safety pharmacology services.

Zyme Communications
Healthcare and Life Science 08 Jun 2023

H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development

Automated parallel bioreactor offering updated with increased capabilities for multi-parameter process development BioXplorer systems are modular and highly configurable with automation, process control, safety monitoring, and data recording enabled through control
Zyme Communications
Healthcare and Life Science 05 Jun 2023

Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that a second milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics ("AffyXell"),

Zyme Communications
Healthcare and Life Science 01 Jun 2023

Pangaea Data awarded strategic partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC)

Pangaea Data awarded strategic partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC) to characterize patients across hard-to-diagnose mental health conditions.

Zyme Communications
Healthcare and Life Science 01 Jun 2023

Avacta acquires Coris Bioconcept, adding a broad range of marketed professional-use rapid tests to the Group

Acquisition consistent with Avacta Diagnostics M&A strategy and complements earlier acquisition of Launch Diagnostics.

Zyme Communications
Healthcare and Life Science 31 May 2023

Cellular Origins launches Constellation, its configurable robotic platform to enable scalable manufacture of advanced therapies

Closed, fully automated, and configurable robotic platform for cell therapy manufacture can achieve 30-fold increase in space efficiency and reduces production costs and labour by 51% and 16-fold respectively Scales cell therapy manufacturing without changing the process used in
Zyme Communications
Healthcare and Life Science 17 May 2023

Closed Loop Medicine and Pharmanovia enter a co-development partnership for precision medicine combination therapeutics

Pharmanovia’s leading medicine brands to be combined with Closed Loop Medicine’s technology to provide dose optimized personalized therapies Global (ex-US) co-development and commercialization partnership to initially focus on next-generation drug + software product
Zyme Communications
Healthcare and Life Science 16 May 2023

H.E.L Group makes senior appointments as it continues to scale globally

Hasan Hallaq, PhD appointed as European Sales Director, Victoria Ordsmith joins as Director of Marketing and Sarennah Longworth-Cook promoted Director of People Appointments will help drive company growth and sales of H.E.L’s laboratory systems for the pharma, biote
Zyme Communications
Healthcare and Life Science, Information Technology and Telecoms 11 May 2023

Cellular Origins partners with ScaleReady to simplify, standardise, and automate cell therapy manufacturing

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), announces collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing. The partnership aims to automate…

Zyme Communications
Healthcare and Life Science 04 May 2023

Global Access Diagnostics (GADx) welcomes new leadership

Global Access Diagnostics (GADx) announces today that Mr Mark Davis is stepping down as CEO and co-founder after 20 years of unwavering service, having created the organisation Mologic Ltd in June 2003 alongside his father and industry leader, Prof. Paul Davis.

Zyme Communications
Healthcare and Life Science 02 May 2023

Gyros Protein Technologies introduces Gyrolab Generic Cyno ADA Kit Reagents to support pre-clinical immunogenicity assessment

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in cyno samples

Zyme Communications
Healthcare and Life Science 27 Apr 2023

First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta’s phase 1 multi-centre trial evaluating the safet

Zyme Communications
Healthcare and Life Science 11 Apr 2023

FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing

Chemically defined media optimized for growth and productivity of CHO cells in perfusion and batch and fed-batch bioprocesses Manufactured to cGMP-compliant standards to support production of recombinant proteins, monoclonal antibodies, and biosimilars
Zyme Communications
Healthcare and Life Science 06 Apr 2023

Avacta opens first two US Clinical Investigator sites for AVA6000 Phase 1 clinical study

Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center now open for patient enrolment to pre|CISION™ lead programme, AVA6000

Zyme Communications
Healthcare and Life Science 05 Apr 2023

Avacta announces first patient dosed in fifth cohort of AVA6000 Phase Ia Dose Escalation Study

Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000.

Zyme Communications
Healthcare and Life Science 04 Apr 2023

Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge Innovation Capital invested Former Novartis SVP appoint
Zyme Communications
Healthcare and Life Science 03 Apr 2023

Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals

Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to ide

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 16
  • Page 17
  • Current page 18
  • Page 19
  • Page 20
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS